Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab to Prevent Oral Cancer in High-Risk Premalignant Lesions
NCT04065737Phase 2Unknown
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Aug 2019
- Primary completion
- Jul 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in Oral Precancerous Lesions, sponsored by Shanghai Ninth People's Hospital. Status: unknown.
02
Drugs
sintilimab
03
Conditions
Oral Precancerous Lesions
Beyond the preview
Go deeper on NCT04065737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04065737.